NEW YORK, March 31, 2017 /PRNewswire/ --
Stock-Callers.com has issued research reports on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). According to a report on Investor's Business Daily, despite a stumble in March, the SPDR S&P Biotech and iShares Nasdaq Biotechnology ETFs are holding on to double-digit gains for the first quarter versus 12% for the S&P 500. You can access our complimentary research reports on these stocks now at:
Shares in Rockville, Maryland-based Rexahn Pharmaceuticals Inc. rose 0.42%, ending Thursday's trading session at $0.48. The stock recorded a trading volume of 1.80 million shares. The Company's shares have surged 96.25% in the last one month, 226.78% over the last three months, and 239.68% on an YTD basis. The stock is trading 70.22% and 109.99% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Rexahn Pharma, which discovers, develops, and commercializes treatments for cancer, have a Relative Strength Index (RSI) of 69.37. Visit us today and download your complete report on RNN for free at:
Bethesda, Maryland headquartered Northwest Biotherapeutics Inc.'s stock declined 0.82%, closing the day at $0.24, with a total trading volume of 723,758 shares. The Company's shares are trading 35.26% below their 50-day moving average. Shares of the Company, which discovers and develops immunotherapy products to treat cancer in the US and internationally, have an RSI of 33.12.
On March 23rd, 2017, Northwest Biotherapeutics announced that the Company has closed on the $7.5 million financing it announced on Friday, March 17th, 2017. The Company sold to several institutional investors securities totaling 28,843,692 shares. The arrangement is to enable investors to avoid exceeding 4.99% ownership while still funding $7.5 million. The complimentary research report on NWBO can be accessed at:
On Thursday, shares in Hampton, New Jersey headquartered Celldex Therapeutics Inc. recorded a trading volume of 3.81 million shares, which was higher than their three months average volume of 1.96 million shares. The stock ended the day 2.96% lower at $3.60. The Company's shares have advanced 1.12% in the past month, 0.56% in the previous three months, and 1.69% on an YTD basis. The stock is trading above its 50-day moving average by 5.48%. Furthermore, shares of Celldex Therapeutics, which focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics, have an RSI of 57.32.
On March 14th, 2017, Celldex Therapeutics reported business and financial highlights for Q4 2016 and the year ended December 31st, 2016. For Q4, total revenue was $1.9 million, R&D expenses were $24.6 million, and net loss was $32.3 million. For the full year, total revenue was $6.8 million, R&D expenses were $102.7 million, and net loss was $128.5 million. Register for free on Stock-Callers.com and download the PDF research report on CLDX at:
Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc.'s stock dropped 0.67%, finishing yesterday's session at $107.29. A total volume of 3.02 million shares was traded, which was above their three months average volume of 1.82 million shares. The Company's shares have advanced 18.80% in the last one month, 43.84% in the previous three months, and 45.64% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 20.91% and 22.36%, respectively. Additionally, shares of Vertex Pharma, which discovers, develops, manufactures, and commercializes medicines for serious diseases, have an RSI of 77.38.
On March 17th, 2017, research firm JMP Securities upgraded the Company's stock rating from 'Market Perform' to 'Market Outperform'.
On March 28th, 2017, Vertex Pharmaceuticals announced results from two Phase-3 studies of the tezacaftor (VX-661) / ivacaftor combination treatment that showed statistically significant improvements in lung function in people with cystic fibrosis ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator gene. Get free access to your research report on VRTX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA